BXQ-350 / Cincinnati Children's Hospital Medical Center, Bexion - LARVOL DELTA

A phase 1b/2 study on the efficacy and safety of BXQ-350, a first-in-class sphingolipid metabolism modulator, in combination with mFOLFOX7 and bevacizumab in newly diagnosed metastatic colorectal carcinoma. (ASCO-GI 2026) - P1, P1/2 | "Research Funding Bexion Pharmaceuticals. Primary endpoints are Cumulative Oxaliplatin Dose, ORR and Safety. Secondary endpoints are OS, PFS, DCR, CIPN, PK/PD and biomarkers."

Clinical • Combination therapy • Metastases • P1/2 data • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

BXQ-350: A NOVEL APPROACH TO ACTIVATE GLUCOSYLCERAMIDASE IN PARKINSON'S DISEASE PATIENTS (ADPD 2026) - "BXQ-350 is a novel biologic that lowers significantly circulating levels of key neurotoxic sphingolipids. In PD models, BXQ-350 rescues Gcase activity in in vitro and in vivo. Results of on-going experiments warrant further investigation of BXQ-350 potential clinical opportunity for the treatment of PD patients."

Clinical • CNS Disorders • Metabolic Disorders • Movement Disorders • Parkinson's Disease • LRRK2

A Phase 1b/2a study to evaluate the efficacy and safety of BXQ-350 in combination with mFOLFOX7 and bevacizumab in newly diagnosed metastatic colorectal carcinoma patients (mCRC): Interim efficacy subset analyses (AACR 2026) - "Abstract is embargoed at this time."

Clinical • Combination therapy • Metastases • P1/2 data • Colorectal Cancer • Oncology • Solid Tumor

BXQ-350 reduces incidence, severity, and time to on-set of chemotherapy induced peripheral neuropathy via modulation of sphingolipid metabolism (AACR 2026) - P1, P1/2 | "Clinically, BXQ-350 was investigated in an adult Phase 1 dose-escalation safety study in heavily pretreated all-comer cancer patients with advanced solid malignancies (NCT02859857), in a Phase 1 Proof of Concept (PoC) study in patients with established chronic CIPN from prior cancer treatments (NCT05291286) and is being investigated in a Phase 1b/2a study in combination with FOLFOX7+ Bevacizumab in newly diagnosed first line mCRC patients (NCT05322590). Preclinical and clinical results suggest that BXQ-350 protects cancer patients from antineoplastic agents known to induce CIPN enabling the administration of higher cumulative doses of oxaliplatin in mCRC patients. A strong correlation was noted between CIPN and LacCer plasma levels and other CIPN biomarkers."

Colorectal Cancer • Oncology • Solid Tumor • Plasma NfL

BXQ-350: A novel biologic that targets dysregulated sphingolipid metabolism and normalizes key anti-tumoral and pro-tumoral sphingolipids in newly diagnosed metastatic colorectal carcinoma patients (mCRC) (AACR 2026) - P1/2 | "BXQ-350 was safe and well tolerated in combination with SoC in 1L mCRC. Ongoing monitoring of patients suggests that BXQ-350 may provide a clinical benefit to 1L mCRC patients in combination with FOLFOX 7 + Bevacizumab. Basal and longitudinal analysis of sphingolipid showed that BXQ-350 impacts plasma levels of critically important sphingolipids and associations between key sphingolipids and survival were noted."

Clinical • Metastases • Colorectal Cancer • Oncology • Solid Tumor

A Phase 1b/2a study to evaluate the efficacy and safety of BXQ-350 in combination with mFOLFOX7 and bevacizumab in newly diagnosed metastatic colorectal carcinoma patients (mCRC): Evidence of lower incidence and severity of CIPN events (AACR 2026) - "Abstract is embargoed at this time."

Clinical • Combination therapy • Metastases • P1/2 data • Colorectal Cancer • Oncology • Solid Tumor

Phosphatidylserine Externalization in Cancer: Biology, Immune Suppression, and Emerging Theragnostic Strategies. (PubMed, Int J Mol Sci) - "We further summarize the development and evaluation of PS-targeted therapeutic platforms-such as bavituximab, SapC-DOPS/BXQ-350, and PS-directed imaging agents-and highlight their translational potential in combination with radiotherapy, chemotherapy, and checkpoint inhibitors. Chronic PS externalization, as manifested through distinct cellular and vesicular carriers, represents a unifying biomarker of tumor stress, immune suppression, and therapeutic vulnerability, offering a next-generation axis for theragnostic cancer management."

Journal • Review • Oncology

Bxq-350 in combination with FOLFOX7 and bevacizumab: Evaluation of effect on oxaliplatin-induced CIPN—A phase 1b/2 trial to assess the efficacy and safety of BXQ-350, a first-in-class sphingolipid metabolism modulator, in newly diagnosed metastatic colorectal carcinoma. (ASCO-GI 2026) - P1/2 | "Results show that BXQ-350 was safe and well tolerated in the combination. Data suggest that BXQ-350 may provide additional clinical benefits and may reduce intensity or delay onset of CIPN, allowing for increased cumulative dosing of oxaliplatin and relative dose intensity in 1L mCRC."

Clinical • Combination therapy • Metastases • P1/2 data • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • CXCL8 • IL10 • IL6

BXQ-350 efficacy and safety evaluation in first line mCRC patients: A phase 1b/2 study of BXQ-350, a first-in-class sphingolipid metabolism modulator, in combination with mFOLFOX7 plus bevacizumab in newly diagnosed metastatic colorectal carcinoma. (ASCO-GI 2026) - P1, P1/2 | "Research Funding Bexion Pharmaceuticals. BXQ-350 was safe and well tolerated in combination with SoC. Ongoing monitoring of patients suggests BXQ-350 when added to SoC may provide additional clinical benefits in this population as compared to natural history of these patients, both in terms of increasing COD & RDI as well as amelioration of CIPN."

Clinical • Combination therapy • Metastases • P1/2 data • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Bexion Pharmaceuticals, Inc. Announces Poster Presentations at the American Society for Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium 2026 (PRNewswire)

P1/2 data • Colorectal Cancer

Effect of BXQ-350, a novel sphingolipid metabolism modulator, on neuronal environments through modulation of gene pathways. (ASCO 2025) - "A suite of genes deemed to be implicated in CIPN were investigated looking at the differences in RNA levels between mice DRGs from the BXQ-350 alone, BXQ-350/Oxaliplatin, Oxaliplatin alone, and vehicle alone groups... CIPN is a dangerous side effect of chemotherapy that causes patients to discontinue treatment courses. BXQ-350 has been shown to reduce the burden of CIPN in vivo and in vitro. Instead of directly counteracting the effects of specific chemotherapeutics, BXQ-350 promotes several pathways that regulate neuronal health, cleaning up neurons and promoting homeostatic neuronal environments."

Metabolic Disorders • Oncology • Pain

A phase 1 study to evaluate the safety and tolerability of BXQ-350, a novel sphingolipid metabolism modulator, in pediatric diffuse intrinsic pontine glioma and diffuse midline glioma. (ASCO 2025) - P1 | "BXQ-350 shows potential as a treatment for pediatric DIPG and DMG. By combining it with standard radiation therapy, this study aims to enhance survival rates in this vulnerable population. Future trials may further define its clinical application and optimize dosing strategies."

Clinical • P1 data • Brain Cancer • CNS Tumor • Diffuse Intrinsic Pontine Glioma • Diffuse Midline Glioma • Glioma • Metabolic Disorders • Oncology • Pediatrics • Solid Tumor

Bexion Pharmaceuticals, Inc. Announces Acceptance of Abstracts at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (PRNewswire) - "Bexion Pharmaceuticals...announced that two abstracts were accepted at the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting..."

Clinical data • Diffuse Intrinsic Pontine Glioma • Glioma

Development of an in-house methodology to analyze large clinical cancer biomarkers datasets (AACR 2025) - "Background: BXQ-350 is a novel biologic that modulates sphingolipid metabolism... Large biomarker data sets are collected in the course of clinical studies to support clinical development. Furthermore, such analyses can support understanding the mechanism of action and guide patient selection. The method developed allows for flexible and granular analysis of biomarkers and correlative analysis across different groups of biomarkers or individual patients and groups of patients"

Biomarker • Clinical • Oncology

Bexion Pharmaceuticals, Inc. Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025 (PRNewswire) - "Bexion Pharmaceuticals...announced that the Company will participate in the American Association for Cancer Research (AACR) Annual Meeting 2025 taking place April 25-30, 2025, in Chicago, Illinois."

Preclinical • Solid Tumor

Sphingolipid modulating compounds BXQ-350 and desipramine display synergy in reducing viability across multiple cancer cell types in vitro (AACR 2025) - "Disrupting a cancer cell's sphingolipid metabolism, specifically the Ceramide-S1P rheostat, is a viable strategy for clinical therapeutics. The synergy BXQ-350 and Desipramine combinations show across cancer cell types, with varying oncogenic profiles, suggests that targeting sphingolipid metabolism is an agnostic approach to treating cancer, not related to any specific mutation or cell type. The possibility exists for sphingolipid modulating drugs to be combined with specific chemotherapeutics to increase their efficacy."

Preclinical • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Pancreatic Cancer • Solid Tumor

RETRO: BXQ-350 Pharmacokinetic/Pharmacodynamic Study in Cancer Patients (clinicaltrials.gov) - P1 | N=21 | Completed | Sponsor: Bexion Pharmaceuticals, Inc. | Active, not recruiting ➔ Completed

Trial completion • Oncology • Pain

BXQ-350, a novel sphingolipid metabolism modulator, in combination with mFOLFOX7 and bevacizumab in newly diagnosed metastatic colorectal cancer (mCRC) patients: A phase 1b/2 randomized study. (ASCO-GI 2025) - P1, P1/2 | "A secondary objective is to determine if BXQ-350 decreases CIPN. Enrollment in the expansion cohort of 30 patients is nearly complete, with 26 patients enrolled as of September 2024."

Clinical • Combination therapy • Metastases • P1/2 data • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Bexion Pharmaceuticals, Inc. Announces Poster Presentation at ASCO GI 2025 (Businesswire) - "Abstract Number: TPS320; Abstract Title: 'BXQ-350, a novel sphingolipid metabolism modulator, in combination with mFOLFOX7 and bevacizumab in newly diagnosed metastatic colorectal cancer (mCRC) patients: A phase 1b/2 study'."

Trial status • Colorectal Cancer

KONQUER: A Study of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) or Diffuse Midline Glioma (DMG) (clinicaltrials.gov) - P1 | N=10 | Terminated | Sponsor: Bexion Pharmaceuticals, Inc. | Trial completion date: Dec 2025 ➔ Oct 2024 | Active, not recruiting ➔ Terminated; Bexion Pharmaceuticals has decided to close the BXQ-350.AD study to enrollment prior to the anticipated enrollment goal. Justification for this decision is due to slow enrollment and the competitive landscape of the indication.

Trial completion date • Trial termination • Brain Cancer • CNS Tumor • Diffuse Intrinsic Pontine Glioma • Diffuse Midline Glioma • Glioma • Oncology • Solid Tumor

ETERNITI: Continued Treatment for Participants Enrolled in Studies of BXQ-350 (clinicaltrials.gov) - P1 | N=5 | Terminated | Sponsor: Bexion Pharmaceuticals, Inc. | N=50 ➔ 5 | Enrolling by invitation ➔ Terminated; Bexion Pharmaceuticals no longer has open studies in which subjects would be eligible to rollover and continue treatment under the BXQ-350.AE protocol. Therefore, no additional subjects will be enrolled in this trial.

Enrollment change • Trial termination • Oncology

RETRO: BXQ-350 Pharmacokinetic/Pharmacodynamic Study in Cancer Patients (clinicaltrials.gov) - P1 | N=21 | Active, not recruiting | Sponsor: Bexion Pharmaceuticals, Inc. | Trial primary completion date: Sep 2024 ➔ Dec 2024

Trial primary completion date • Oncology • Pain

ASIST: BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma (clinicaltrials.gov) - P1/2 | N=195 | Active, not recruiting | Sponsor: Bexion Pharmaceuticals, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Metastases • Colon Adenocarcinoma • Colon Cancer • Colorectal Adenocarcinoma • Colorectal Cancer • Oncology • Pain • Solid Tumor

Bexion Pharmaceuticals, Inc. Announces Completion of Enrollment in Open Label Portion of Phase 1b/2 ASIST Study in mCRC (PRNewswire) - "Bexion Pharmaceuticals, Inc...announced completion of enrollment in the open label portion of Phase 1b/2 ASIST study of BXQ-350 in combination with Standard-of-Care (SOC) for the first line treatment of metastatic colorectal cancer (mCRC)....'We are excited about advancing to the next stage of clinical development, including further discussions with FDA on study design, and we look forward to providing updates as we reach upcoming milestones in 2025'."

Enrollment status • Colorectal Cancer

Bexion Pharmaceuticals, Inc. Awarded Grant from The Michael J. Fox Foundation to Advance BXQ-350 (PRNewswire) - "Bexion Pharmaceuticals...announced today that The Michael J. Fox Foundation for Parkinson's Research (MJFF) awarded a $1.4M grant to Bexion. The grant will fund the preclinical development of BXQ-350 for the treatment of Parkinson's disease (PD)."

Financing • Parkinson's Disease